News NICE relents, ending postcode access to prostate cancer drug Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.
Sales & Marketing Why pharmacy-based engagement is pharma’s untapped adherence... Pharma companies can work alongside pharmacists to deliver personalised outreach that informs patient treatment decisions and drives adherence.
Oncology The cancer community must seize the opportunity of the Natio... With the government’s National Cancer Plan due for publication this autumn, we have an opportunity to fundamentally improve how we deliver innovation.
Market Access Unlocking oncology access: What the OECD findings mean for m... New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.
News Barriers are limiting UK childhood vaccination, say doctors Vaccination rates for children are declining in the UK, but it's not just because of vaccine hesitancy.
Patients Innovation without access is just a headline: Closing the ga... More than 4.5 billion people - over half the world’s population - lack full coverage of essential health services.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.